FOXP3 and cancer: The results of the pooled analysis revealed no significant association between the FOXP3 gene polymorphisms and the cancer risk (for rs3761549: TT vs. CT+CC OR, 1.20, 95% CI, 0.87–1.66; TT+CT vs. CC OR, 0.74, 95% CI, 0.41–1.33; TT vs. CC OR, 1.06, 95% CI, 0.76–1.46; TC vs. CC OR, 0.56, 95% CI, 0.17–1.80; T vs. C OR, 0.94, 95% CI, 0.83–1.06.